Inflammatory carcinoma of the breast.A Pathologic Definition

Ellis, David L.; Teitelbaum, Steven L.

doi:10.1002/1097-0142(197404)33:4<1045::aid-cncr2820330422>3.0.co;2-m

Cited by 108 publications

(31 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Taylor and Meltzer described IBC as a clinical entity, in which dermal lymphatic invasion offered "pathologic proof" [87],confirming but not denying the diagnosis. Ellis and Teitelbaum along with Saltzstein preferred the pathologic over the clinical definition for IBC [36,74], proposing the alternate phrase "dermal lymphatic carcinomatosis of the breast" [36].…”

Section: Pevmentioning

confidence: 99%

Epidemiology of Inflammatory Breast Cancer (IBC)1

et al. 2006

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with unknown etiology and generally poor outcome. It is characterized by diffuse edema (peau d'orange) and redness (erythema), although either the disease itself or case definitions have varied over time and place, confounding temporal trends and geographic variations. In this review, we discuss case definitions for IBC and its clinical characteristics; describe its geographic variation, age and racial distribution, incidence and survival patterns, and summarize the very limited information on its epidemiologic risk factors. We also incorporate emerging data from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. KeywordsInflammatory breast cancer; epidemiology; etiologic factors Case Definition for Inflammatory Breast Cancer (IBC)IBC is an aggressive and lethal form of breast cancer. It is characterized by the clinical appearance of inflammation, with edema and redness of the breast. However, the appearance of inflammation is not due to true physiologic inflammatory response but rather due to pathologic plugging of the dermal lymphatics of the breast with tumor emboli. This condition was first described in 1814 by Sir Charles Bell [14]; but, it was not until 1924 that the term inflammatory breast cancer was proposed by Lee and Tannebaum at the suggestion of James Ewing [56,88]. Prior to this designation, IBC was referred to as von Volkmann's or Wokmann's syndrome in pregnant women, lactation cancer, carcinoma mastitoides, mastitis carcinomatosa, acute encephaloid cancer, acute mammary carcinoma, acute mammary carcinomatosis, acute brawny cancer, acute scirrhous carcinoma, acute medullary carcinoma or carcinoma telangiectaticum [42,53,55,57,71,75,82,90,92]. In all, these expressions implied an acute and aggressive breast cancer, more of a clinical than a pathological entity, often multifocal [13,18,19,33,38,66,75,92], and occurring in young women during pregnancy or lactation [53,55,75,90].The extent of clinical signs required for IBC has not been standardized and has varied from any edema (peau d'orange) and redness (erythema) to edema and redness covering the entire

show abstract

Section: Pevmentioning

confidence: 99%

Epidemiology of Inflammatory Breast Cancer (IBC)1

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Underlying palpable masses are not always seen and are not required for diagnosis [14]. The clinical appearance of inflammation is due to the lymphatic obstruction that results from the tumor emboli invading the dermal lymphatic vessels in the breast [15]; this inflammation does not appear to result from the infiltration of lymphocytes or other inflammatory mediators [16–18]. …”

Section: Introductionmentioning

confidence: 99%

Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer

Denu

Hampton

Currey

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

Purpose Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer for which treatments vary, so we sought to identify factors that affect the receipt of guideline-concordant care. Methods Patients diagnosed with IBC in 2004 were identified from the Breast and Prostate Cancer Data Quality and Patterns of Care Study, containing information from cancer registries in seven states. Variation in guideline-concordant care for IBC, based on National Comprehensive Cancer Network (NCCN) guidelines, was assessed according to patient, physician, and hospital characteristics. Results Of the 107 IBC patients in the study without distant metastasis at the time of diagnosis, only 25.8% received treatment concordant with guidelines. Predictors of non-concordance included patient age (≥70 years), non-white race, normal body mass index (BMI 18.5–25 kg/m2), patients with physicians graduating from medical school >15 years prior, and smaller hospital size (<200 beds). IBC patients survived longer if they received guideline-concordant treatment based on either 2003 (p=0.06) or 2013 (p=0.06) NCCN guidelines. Conclusions Targeting factors associated with receipt of care that is not guideline-concordant may reduce survival disparities in IBC patients. Prompt referral for neoadjuvant chemotherapy and postoperative radiation therapy is also crucial.

show abstract

“…12 Also included in this diagnosis were patients without the clinical symptomatology but with pathologically confirmed findings of breast carcinoma within the dermal lymphatics. 13,14 Staging was performed using the TNM system as proposed by the American Joint Commission on Cancer. 15 Lesions were classified as T4d based on the clinicopathologic evidence of diffuse brawny skin induration of the breast with an erysipeloid edge, usually without an underlying palpable mass.…”

Section: Methodsmentioning

confidence: 99%

Beyond Palliative Mastectomy in Inflammatory Breast Cancer?A Reassessment of Margin Status

et al. 1999

View full text Add to dashboard Cite

This study suggests that in patients with inflammatory breast cancer and nonmetastatic disease, an aggressive surgical approach may be justified with the goal of a negative surgical margin. Achievement of this local control is associated with a better overall outcome for this subset of patients. The ability to obtain negative margins may further identify a group of patients with a less aggressive tumor biology that may be more responsive to other modalities of therapy.

show abstract

Inflammatory carcinoma of the breast.A Pathologic Definition

Cited by 108 publications

References 1 publication

Epidemiology of Inflammatory Breast Cancer (IBC)1

Epidemiology of Inflammatory Breast Cancer (IBC)1

Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer

Beyond Palliative Mastectomy in Inflammatory Breast Cancer?A Reassessment of Margin Status

Contact Info

Product

Resources

About